Bristol-Myers Squibb (BMY) Announces FDA Approval of Opdivo Combo for dvanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
Go back to Bristol-Myers Squibb (BMY) Announces FDA Approval of Opdivo Combo for dvanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma
April 16, 2021 1:10 PM EDT
Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1
PRINCETON, N.J.--(BUSINESS WIRE)--
Â
U.S. Food and Drug... More